Ita-as, Dante U.
HRN: 26-51-57 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/02/2025
CEFTAZIDIME 1GM (VIAL)
02/02/2025
02/22/2025
IV
1g
Q8
CAP-MR; Decubitus Ulcer
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes